<DOC>
	<DOCNO>NCT00733577</DOCNO>
	<brief_summary>This escalate dose study subject T2DM , consist four overlap cohort receive 6 day SB756050 ass safety , pharmacokinetics , pharmacodynamics .</brief_summary>
	<brief_title>A Study Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days Dosing .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female subject , 18 60 year age , inclusive , time signing inform consent A female subject eligible participate nonchildbearing potential , define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . FSH estradiol level check Screening postmenopausal woman . Simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory . Except note elsewhere , subject significant know medical condition T2DM , determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test ECGs . A subject clinical abnormality laboratory parameter meet exclusion criterion outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . BMI ( body mass index ) within range 2535 kg/m2 , inclusive . T2DM diagnose least 3 month prior Screening Subjects must treat T2DM use one follow regimen : Diet exercise therapy , Metformin monotherapy , Sulfonylurea monotherapy , Metformin sulfonylurea combination , DPPIV inhibitor , either monotherapy combination agent ( ) list half maximal dose less , Exenatide , either monotherapy combination agent ( ) list All dose antidiabetic medication must stable least 3 month prior Screening , subject must willing wash antidiabetic medication Day 7 Day 7 . Capable give write informed consent , include compliance requirement restriction list consent form . Has positive prestudy Hepatitis B surface antigen positive Hepatitis C , result within 3 month screen . Positive test HIV antibody . History uncorrected thyroid dysfunction . ALT and/or AST &gt; 2 time upper limit normal screening . Fasting triglyceride &gt; 450mg/dL screening . Total Bilirubin &gt; 1.5 time upper limit normal screening . A positive prestudy drug/urine screen tobacco screen . Significant renal disease Significant ECG abnormalities Systolic pressure &gt; 150 mmHg &lt; 80 mmHg diastolic blood pressure &gt; 95 mmHg &lt; 60 mmHg screening . Previous use insulin treatment within 3 month Screening , &gt; 2 week use acute illness last 12 month prior Screening , use 1 year associate GDM . Has history gastrointestinal disease could affect absorption within past year , Gastrointestinal surgery , Chronic acute pancreatitis . History regular alcohol consumption Smoked use tobacco nicotinecontaining product within previous 6 month . Has participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Exposure four new chemical entity within 12 month prior first dose day . Is take prohibited medication . Unwilling abstain caffeineor xanthinecontaining product 24 hour prior dose Day 7 , Use illicit drug nicotinecontaining product , Alcohol 24 hour prior dose Day 7 , Consumption red wine , Seville oranges , grapefruit grapefruit juice 7 day prior first dose study medication collection final pharmacokinetic blood sample History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation . This include sensitivity heparin , heparin use maintain catheter patency . Where participation study would result donation blood excess 500 mL within 56 day period . Subject either immediate family member participate investigator , study coordinator , employee investigator ; member staff conduct study . Unwillingness inability follow procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>diabetes</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>